An interesting report......for a "broad overview" of the CDN HC sector. Makes for a good read on a rainy day.
Enjoy the week-end, rg
An excerpt...Looking Forward – Canadian Event Pipeline
There are many products currently in pivotal clinical trials or under regulatory review which could provide significant individual company events.• Products which are currently in or ready for pivotal studies––Aeterna Zentaris – perifosine for multiple myeloma with partner Keryx Biopharmaceuticals––Allon Therapeutics – davunetide for PSP––BELLUS Health – KIACTATM for Amyloid A amyloidosis with partner Celtic Therapeutic––Bioniche Life Sciences – UrocidinTM for bladder cancer with partner Endo Pharmaceuticals––Helix BioPharma – topical interferon alpha-2b for low-grade cervical lesions––Isotechnika – voclosporin for transplant; also for noninfectious uveitis by partner Lux Biosciences––Oncolytics Biotech – REOLYSIN® for head & neck cancer––Spectral Diagnostics – ToraymyxinTM for severe sepsis––Trimel Pharmaceuticals – Compleo TRT for male hypogonadism
My take-away from above...there are few products of Urocidin's status/standing here in Canada. Urocidin and Bioniche s/b much better known to Cdn investors (nothing new to posters here). Hence, my interest in their next report, a recent survey re IR (below). I did not realize that TMX Equicom is an IR firm so not exactly objective, but interesting. And, as I signed-in to receive survey results, if they call I will recommend they talk to Mr. McRae and Ms. Shea.
Survey says... "98% of the investment community agree IR has an effect on a company's market valuation." For complete survey results, please click here
If above link not "live"...the link below should take you directly to survey results and avoid the need to sign-in.
https://www.equicomgroup.com/survey/TMX%20Equicom%20Survey%20-%20The%20Impact%20of%20Investor%20Relations%20on%20Valuation.pdf